Table 2.
Effects of antibiotics in the treatment of COVID-19 pneumonia on 30-day mortality.
| 30-Day Mortality | |||
|---|---|---|---|
| Characteristics | Univariate analysis Odd ratio (95% CI) |
Multivariate analysis Odd ratio (95% CI) |
p |
| Age, years, median, IQR | 1.175 (1.100–1.259) | 1.265 (1.070–1.495) | 0.006 |
| Male (%) | 1.245 (0.356–4.356) | - | |
| Charlson’s score | 1.536 (1.114–2.118) | 0.860 (0.392–1.887) | 0.707 |
| Peak white cell count, 109/L | 1.016 (0.996–1.036) | - | |
| Peak C-reactive protein, mg/L | 1.015 (1.008–1.021) | 1.021 (1.002–1.039) | 0.023 |
| ICU admission at diagnosis of COVID-19 pneumonia (%) |
5.298 (1.453–19.307) | 0.024 (0.000–9.285) | 0.219 |
| Fraction of inspired oxygen, %, median, IQR | 1.041 (1.019–1.064) | 0.939 (0.863–1.021) | 0.140 |
| Mechanical ventilation | 8.727 (2.0314–37.493) | 470.581 (0.682–324642.500) | 0.065 |
| CURB-65 a | 3.897 (2.141–7.094) | 1.351 (0.382–4.786) | 0.470 |
| Remdesivir | 4.631 (1.139–18.836) | 1.703 (0.135–21.467) | 0.680 |
| Documented suspected or confirmed bacterial infection | 14.286 (3.640–56.061) | 0.652 (0.053–7.967) | 0.738 |
| Antibiotic therapy | 31.076 (3.904–247.400) | 14.492 (0.533–393.875) | 0.113 |
a CURB-65 score for pneumonia severity. Only variables with p < 0.05 on univariate analysis were included in the multivariate mode. CI: confidence interval.